Inflammation, DNA methylation and colitis-associated cancer

Carcinogenesis

Volumn 33, Issue 4, 2012, Pages 723-731

  Hartnett, Lori ^a   Egan, Laurence J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; AZACITIDINE; CHEMOKINE; CYTOKINE; CYTOSINE; GROWTH FACTOR; HYDRALAZINE; NUCLEOSIDE ANALOG; PROCAINAMIDE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER RISK; CARCINOGENESIS; CATALYSIS; CHRONIC INFLAMMATION; COLITIS; COLORECTAL CANCER; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DNA METHYLATION; ENTERITIS; EPIGENETICS; EPITHELIUM CELL; GASTROINTESTINAL DYSPLASIA; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; INTESTINE EPITHELIUM; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

EID: 84857577343     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs006     Document Type: Review

References (130)

1. Karin, M. et al. (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol., 5, 749-759.
2. Mantovani, A. et al. (2008) Cancer-related inflammation. Nature, 454, 436-444.
3. Westbrook, A. M. et al. (2010) Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat. Res., 705, 40-59.
4. Ulrich, C. M. et al. (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat. Rev. Cancer, 6, 130-140.
5. Ruder, E. H. et al. (2011) Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am. J. Gastroenterol., 106, 1340-1350.
6. Danese, S. et al. (2010) Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene, 29, 3313-3323.
7. Bernstein, C. N. et al. (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer, 91, 854-862.
8. Genta, R. M. (2003) The gastritis connection: prevention and early detection of gastric neoplasms. J. Clin. Gastroenterol., 36, S44-S49; discussion S61-S62.
9. McKay, C. J. et al. (2008) Chronic inflammation and pancreatic cancer. Best Pract. Res. Clin. Gastroenterol., 22, 65-73.
10. Zhang, H. Y. et al. (2009) Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett., 275, 170-177.
11. Hanauer, S. B. (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis., 12 (suppl. 1), S3-S9.
12. Asquith, M. et al. (2010) An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer. J. Exp. Med., 207, 1573-1577.
13. Bernstein, C. N. et al. (1999) Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am. J. Epidemiol., 149, 916-924.
14. Molodecky, N. A. et al. (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142, 46-54.
15. Colotta, F. et al. (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 30, 1073-1081.
16. Rizzello, F. et al. (2002) Review article: monitoring activity in ulcerative colitis. Aliment. Pharmacol. Ther., 16 (suppl. 4), 3-6.
17. Kanneganti, M. et al. (2011) Animal models of colitis-associated carcinogenesis. J. Biomed. Biotechnol., 2011, 342637.
18. Hsieh, C. J. et al. (1998) Hypermethylation of the p. 16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res., 58, 3942-3945.
19. Fleisher, A. S. et al. (2000) Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res., 60, 4864-4868.
20. Itzkowitz, S. H. et al. (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol., 287, G7-G17.
21. Rutter, M. et al. (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology, 126, 451-459.
22. Moriyama, T. et al. (2007) Hypermethylation of p. 14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis. Dis. Colon Rectum, 50, 1384-1392.
23. Wang, F. Y. et al. (2008) Aberrant DNA methylation in ulcerative colitis without neoplasia. Hepatogastroenterology, 55, 62-65.
24. Cho, J. H. et al. (2011) Recent insights into the genetics of inflammatory bowel disease. Gastroenterology, 140, 1704-1712.
25. Thompson, A. I. et al. (2011) Genetics of ulcerative colitis. Inflamm. Bowel Dis., 17, 831-848.
26. Di Girolamo, N. et al. (1997) Expression of TNF-alpha by human plasma cells in chronic inflammation. J. Leukoc. Biol., 61, 667-678.
27. Noguchi, M. et al. (1998) Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut, 43, 203-209.
28. Huang, S. et al. (1999) Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J. Interferon Cytokine Res., 19, 697-703.
29. Zimmerman, N. P. et al. (2008) Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm. Bowel Dis., 14, 1000-1011.
30. Bollrath, J. et al. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 15, 91-102.
31. Grivennikov, S. et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 15, 103-113.
32. Toyota, M. et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA, 96, 8681-8686.
33. Geboes, K. et al. (1999) Dysplasia in inflammatory bowel diseases: definition and clinical impact. Can. J. Gastroenterol., 13, 671-678.
34. Rabinovitch, P. S. et al. (1999) Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res., 59, 5148-5153.
35. Feagins, L. A. et al. (2009) Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat. Rev. Gastroenterol. Hepatol., 6, 297-305.
36. Grivennikov, S. I. et al. (2010) Immunity, inflammation, and cancer. Cell, 140, 883-899.
37. Hahn, M. A. et al. (2008) Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res., 68, 10280-10289.
38. Popivanova, B. K. et al. (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest., 118, 560-570.
39. Kim, Y. J. et al. (2010) Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prev. Res. (Phila.), 3, 1314-1333.
40. Kujawski, M. et al. (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest., 118, 3367-3377.
41. Rius, J. et al. (2008) NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature, 453, 807-811.
42. Joyce, J. A. et al. (2009) Microenvironmental regulation of metastasis. Nat. Rev. Cancer, 9, 239-252.
43. Leibovich, S. J. et al. (1987) Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature, 329, 630-632.
44. Orosz, P. et al. (1993) Enhancement of experimental metastasis by tumor necrosis factor. J. Exp. Med., 177, 1391-1398.
45. Sartor, R. B. (1997) Review article: how relevant to human inflammatory bowel disease are current animal models of intestinal inflammation? Aliment. Pharmacol. Ther., 11 (suppl. 3), 89-96; discussion 96-97.
46. Wirtz, S. et al. (2007) Mouse models of inflammatory bowel disease. Adv. Drug. Deliv. Rev., 59, 1073-1083.
47. Lin, W. W. et al. (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest., 117, 1175-1183.
48. Szlosarek, P. et al. (2006) Tumour necrosis factor-alpha as a tumour promoter. Eur. J. Cancer, 42, 745-750.
49. Travassos, W. J. et al. (2005) Infliximab: use in inflammatory bowel disease. Curr. Treat. Options Gastroenterol., 8, 187-196.
50. Esfandi, F. et al. (2006) Interleukin-6 level in patients with colorectal cancer. Cancer Lett., 244, 76-78.
51. Li, Y. et al. (2010) Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut, 59, 227-235.
52. Matsumoto, S. et al. (2010) Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J. Immunol., 184, 1543-1551.
53. Foran, E. et al. (2010) Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6. Mol. Cancer Res., 8, 471-481.
54. Berg, D. J. et al. (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J. Clin. Invest., 98, 1010-1020.
55. Schottelius, A. J. et al. (1999) Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J. Biol. Chem., 274, 31868-31874.
56. Hoentjen, F. et al. (2005) STAT3 regulates NF-kappaB recruitment to the IL-12p. 40 promoter in dendritic cells. Blood, 105, 689-696.
57. Sutherland, L. et al. (1991) Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut, 32, 1071-1075.
58. Videla, S. et al. (1994) Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut, 35, 1090-1097.
59. Schuppler, M. et al. (2004) An abundance of Escherichia coli is harbored by the mucosa-associated bacterial flora of interleukin-2-deficient mice. Infect. Immun., 72, 1983-1990.
60. Rakoff-Nahoum, S. et al. (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell, 118, 229-241.
61. Araki, A. et al. (2005) MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J. Gastroenterol., 40, 16-23.
62. Beutler, B. (2004) Inferences, questions and possibilities in toll-like receptor signalling. Nature, 430, 257-263.
63. Greten, F. R. et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118, 285-296.
64. Nenci, A. et al. (2007) Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature, 446, 557-561.
65. Grivennikov, S. I. et al. (2010) Dangerous liaisons: sTAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev., 21, 11-19.
66. Rogler, G. et al. (1998) Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology, 115, 357-369.
67. Yu, H. G. et al. (2003) Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology, 65, 37-45.
68. Zhong, Z. et al. (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science, 264, 95-98.
69. Heinrich, P. C. et al. (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J, 334, (Pt 2), 297-314.
70. He, B. et al. (2003) SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc. Natl Acad. Sci. USA, 100, 14133-14138.
71. Strober, W. et al. (2007) The fundamental basis of inflammatory bowel disease. J. Clin. Invest., 117, 514-521.
72. Hugot, J. P. et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 411, 599-603.
73. Ogura, Y. et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 411, 603-606.
74. Costello, C. M. et al. (2005) Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med, 2, e199.
75. Saito, S. et al. (2011) DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status. Inflamm. Bowel Dis., 17, 1955-1965.
76. Kondo, Y. (2009) Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med. J., 50, 455-463.
77. Fazzari, M. J. et al. (2010) Introduction to epigenomics and epigenomewide analysis. Methods Mol. Biol., 620, 243-265.
78. Glauben, R. et al. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol., 176, 5015-5022.
79. Jenuwein, T. et al. (2001) Translating the histone code. Science, 293, 1074-1080.
80. Glauben, R. et al. (2008) Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut, 57, 613-622.
81. Marks, P. et al. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer, 1, 194-202.
82. Garcia-Manero, G. et al. (2008) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood, 112, 981-989.
83. Fatemi, M. et al. (2002) Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA. Eur. J. Biochem., 269, 4981-4984.
84. Jair, K. W. et al. (2006) De novo CpG island methylation in human cancer cells. Cancer Res., 66, 682-692.
85. Jeltsch, A. (2006) On the enzymatic properties of Dnmt1: specificity, processivity, mechanism of linear diffusion and allosteric regulation of the enzyme. Epigenetics, 1, 63-66.
86. Jones, P. A. et al. (1999) Cancer epigenetics comes of age. Nat. Genet., 21, 163-167.
87. Szyf, M. (2009) Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol., 49, 243-263.
88. Bestor, T. H. et al. (1992) CpG islands in mammalian gene promoters are inherently resistant to de novo methylation. Genet. Anal. Tech. Appl., 9, 48-53.
89. Estellar, M. (2005) Aberrant DNA methylation as a cancer inducing mechanism. Annu. Rev. Pharmacol. Toxicol., 45, 629-656.
90. Etoh, T. et al. (2004) Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am. J. Pathol., 164, 689-699.
91. Ding, W. J. et al. (2008) The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer. Dig. Dis. Sci., 53, 2083-2089.
92. Wehbe, H. et al. (2006) Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res., 66, 10517-10524.
93. Issa, J. P. et al. (2001) Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res., 61, 3573-3577.
94. Maekita, T. et al. (2006) High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res., 12, 989-995.
95. Huang, Y. W. et al. (2010) An overview of epigenetics and chemoprevention. FEBS Lett., 585, 2129-2136.
96. Alvarez, H. et al. (2011) Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet., 7, e1001356.
97. Tominaga, K. et al. (2005) Prediction of colorectal neoplasia by quantitative methylation analysis of estrogen receptor gene in nonneoplastic epithelium from patients with ulcerative colitis. Clin. Cancer Res., 11, 8880-8885.
98. Dhir, M. et al. (2008) Epigenetic regulation ofWNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J. Gastrointest. Surg., 12, 1745-1753.
99. Tahara, T. et al. (2009) Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin. Exp. Med., 9, 125-130.
100. Arasaradnam, R. P. et al. (2010) DNA methylation of ESR-1 and N-33 in colorectal mucosa of patients with ulcerative colitis (UC). Epigenetics, 5, 422-426.
101. Tahara, T. et al. (2009) Effect of MDR1 gene promoter methylation in patients with ulcerative colitis. Int. J. Mol. Med., 23, 521-527.
102. Kominsky, D. J. et al. (2011) An endogenously anti-inflammatory role for methylation in mucosal inflammation identified through metabolite profiling. J. Immunol., 186, 6505-6514.
103. Katsurano, M. et al. (2012) Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction. Oncogene, 31, 342-351.
104. O'Hagan, H. M. et al. (2011) Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG islands. Cancer Cell, 20, 606-619.
105. Lal, G. et al. (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol., 182, 259-273.
106. Deaton, A. M. et al. (2011) Cell type-specific DNA methylation at intragenic CpG islands in the immune system. Genome Res., 21, 1074-1086.
107. Issa, J. P. (2004) CpG island methylator phenotype in cancer. Nat. Rev. Cancer, 4, 988-993.
108. Konishi, K. et al. (2007) Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology, 132, 1254-1260.
109. Sanchez, J. A. et al. (2011) Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer. Inflamm. Bowel Dis.
110. Hur, K. et al. (2011) Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation. Carcinogenesis, 32, 35-41.
111. Niwa, T. et al. (2010) Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res., 70, 1430-1440.
112. Ball, M. P. et al. (2009) Targeted and genome-scale strategies reveal genebody methylation signatures in human cells. Nat. Biotechnol., 27, 361-368.
113. Doi, A. et al. (2009) Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet., 41, 1350-1353.
114. Weber, M. et al. (2005) Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet., 37, 853-862.
115. Khulan, B. et al. (2006) Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res., 16, 1046-1055.
116. Lister, R. et al. (2009) Human DNA methylomes at base resolution show widespread epigenomic differences. Nature, 462, 315-322.
117. Irizarry, R. A. et al. (2008) Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res., 18, 780-790.
118. Harris, R. A. et al. (2010) Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat. Biotechnol., 28, 1097-1105.
119. Figueroa, M. E. et al. (2008) An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One, 3, e1882.
120. Pastor, W. A. et al. (2011) Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature, 473, 394-397.
121. Stroud, H. et al. (2011) 5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol., 12, R54.
122. Ito, S. et al. (2010) Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature, 466, 1129-1133.
123. Williams, K. et al. (2011) TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature, 473, 343-348.
124. Xu, Y. et al. (2011) Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell, 42, 451-464.
125. Li, W. et al. (2011) Distribution of 5-hydroxymethylcytosine in different human tissues. J. Nucleic Acids, 2011, 870726.
126. Pronier, E. et al. (2011) Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulo-monocytic differentiation of human hematopoietic progenitors. Blood, 118, 2551-2555.
127. Ito, S. et al. (2011) Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science, 333, 1300-1303.
128. Jones, P. A. et al. (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell, 20, 85-93.
129. Issa, J. P. (2007) DNA methylation as a therapeutic target in cancer. Clin. Cancer Res., 13, 1634-1637.
130. Kuendgen, A. et al. (2008) Current status of epigenetic treatment in myelodysplastic syndromes. Ann. Hematol., 87, 601-611.